NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
Rhea-AI Summary
NovaBridge (Nasdaq: NBP) will ring the Nasdaq Opening Bell on Friday, January 2, 2026 at 9:15 AM ET, with Executive Chairman Fu Wei, CEO Sean Fu and members of management participating.
The company also announced inclusion in the Nasdaq Biotech Index (NBI), effective December 19, 2025, which the company says increases visibility and underscores its position as a global biotech platform focused on accelerating access to innovative medicines.
The bell-ringing ceremony will be held in Times Square and streamed live via Nasdaq’s bell-ringing webcast.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Clinical data update | Positive | +1.7% | Phase 1 ragistomig dose-expansion data with improved safety profile. |
| Dec 03 | Clinical data preview | Positive | +4.9% | Announcement of expanded Phase 1 ragistomig data presentation at ESMO-IO. |
| Nov 20 | Management appointments | Positive | -7.5% | Visara leadership hires to advance VIS-101 toward Phase 3 readiness. |
Recent clearly positive clinical updates saw mixed reactions, while another constructive operational update drew a sharp selloff, showing inconsistent trading responses to good news.
This announcement follows several clinically and operationally positive updates in late 2025. On Dec 10, NovaBridge reported encouraging Phase 1 ragistomig data with improved safety and saw a modest +1.74% move. A week earlier, on Dec 3, the company flagged expanded Phase 1 data to be presented at ESMO‑IO, which coincided with a stronger +4.94% reaction. By contrast, management appointments at Visara on Nov 20, supporting VIS‑101’s path toward being Phase‑3‑ready in 2026, were followed by a -7.51% decline. Today’s index inclusion and bell-ringing fit the recent theme of visibility-building milestones.
Market Pulse Summary
This announcement highlights NovaBridge’s growing visibility, with inclusion in the Nasdaq Biotech Index effective Dec 19, 2025 and plans to ring the opening bell on Jan 2, 2026. It follows recent positive clinical data updates and a 6-K showing a narrowed net loss of $15.5 million and cash of $228.1 million. Investors may watch how index membership, the platform strategy, and future clinical milestones for ragistomig and VIS‑101 influence NovaBridge’s execution and capital needs.
Key Terms
Nasdaq Biotech Index financial
AI-generated analysis. Not financial advice.
NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader
- Opening the first trading session of the New Year marks an excellent beginning to 2026 for NovaBridge
- Inclusion in the Nasdaq Biotech Index (NBI) enhances NovaBridge’s visibility and emphasizes the Company’s position as an industry leader
ROCKVILLE, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced Fu Wei, Executive Chairman of NovaBridge, will ring the Nasdaq Opening Bell on Friday, January 2, 2026, along with Sean Fu, PhD, Chief Executive Officer of NovaBridge and members of the Management Team. In addition, the Company announced that NovaBridge joined the Nasdaq Biotech Index, effective December 19, 2025.
“Ringing the opening bell for the first Nasdaq trading session of 2026 is profoundly fitting with NovaBridge’s mission! There is no better place than this “crossroads of the world” to celebrate NovaBridge’s successful transition to a global biotech platform in 2025, and to share our vision for unlocking shareholder value in 2026, as we bridge collaboration, translational science and execution to rapidly progress transformative therapies,” said Fu Wei, Executive Chairman of NovaBridge.
Sean Fu, PhD, Chief Executive Officer of NovaBridge commented, “Inclusion in the Nasdaq Biotech Index marks a notable milestone for NovaBridge that underscores the strength of our strategic vision and pipeline. It befits NovaBridge as an industry leader and enhances the Company’s visibility as we leverage our hub-and-spoke business model to accelerate the development of innovative medicines.”
Overview of Event Details
Nasdaq Bell Ringing Ceremony
- Event Date and Time: Friday, January 2, 2026, 9:15 – 9:35 AM ET
- NovaBridge Participants: Fu Wei, Executive Chairman; Sean Fu, CEO; and members of Management
- Location: Times Square, New York
- Event Livestream Link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. We combine deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, and VIS-101, a second-in-class, potentially best-in-class bifunctional biologic, targeting VEGF-A and ANG2.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is currently completing a large, randomized, dose-ranging Phase 2 study for wet AMD. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
For more information, please visit https://www.novabridge.com and follow us on LinkedIn.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. NovaBridge may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the effect of the Company’s inclusion in the Nasdaq Biotech Index; the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates; the strategic and clinical development of NovaBridge’s drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101; anticipated clinical milestones and results, and related timing. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
NovaBridge Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
FAQ
When will NovaBridge (NBP) ring the Nasdaq Opening Bell?
Who from NovaBridge will participate in the Nasdaq bell-ringing on January 2, 2026?
When did NovaBridge (NBP) join the Nasdaq Biotech Index (NBI)?
Where will the NovaBridge Nasdaq bell-ringing take place and how can investors watch?
What does inclusion in the Nasdaq Biotech Index mean for NovaBridge (NBP)?
